Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with... We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following multiple crizotinib 250-mg twice-daily dosing in patients with ALK-positive cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Epidemiology, Biomarkers and Prevention Pubmed

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.

Cancer Epidemiology, Biomarkers and Prevention , Volume 22 (23): 7 – Jan 16, 2018

Clinical Implications of the Pharmacokinetics of Crizotinib in Populations of Patients with Non-Small Cell Lung Cancer.


Abstract

We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following multiple crizotinib 250-mg twice-daily dosing in patients with ALK-positive cancer.

Loading next page...
 
/lp/pubmed/clinical-implications-of-the-pharmacokinetics-of-crizotinib-in-r1eGZjStCE

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1078-0432
DOI
10.1158/1078-0432.CCR-16-0536
pmid
27281559
Publisher site
See Article on Publisher Site

Abstract

We assessed the effect of baseline patient demographic and disease characteristics on the crizotinib pharmacokinetic parameters oral clearance (CL/F), volume of distribution (V2/F), and area under the curve at steady state (AUCss) following multiple crizotinib 250-mg twice-daily dosing in patients with ALK-positive cancer.

Journal

Cancer Epidemiology, Biomarkers and PreventionPubmed

Published: Jan 16, 2018

There are no references for this article.